1. Role Of Recombinant Human Premix Insulin (Rhi 50/50) In The Management Of Type 2 Diabetes Mellitus In Asian Population: An Expert Review

Introduction-

The prevalence of type 2 diabetes (T2D) is increasing at exponential rates, the estimated prevalence of diabetes in adults aged 20–79 years has more than tripled, from an estimated 151 million (4.6% of the global population at the time) to 537 million (10.5%). 643 million people will have diabetes by 2030. If trends continue, the number will jump to a staggering 783 million (12.2%) by 2045. Almost 90% of people with undiagnosed diabetes live in low- and middle-income countries. India accounts for 1 in 7 of all adults living with diabetes worldwide. Asian Indians have a higher predilection for T2DM, and this is due to the ‘Asian-Indian phenotype. Dietary carbohydrates form the major source of energy in Asian diets. There have also been rapid changes in the dietary composition of Asian Indians such that diets today are high in refined carbohydrates, sugars, fats, and salt. All these factors contribute to the rising prevalence of diabetes, hypertension, and cardiovascular diseases (CVDs). The carbohydrate quantity and quality play a vital function in the management of diabetes. High glycaemic index foods elicit higher glycaemic and insulinemic responses and promote insulin resistance and type 2 diabetes (T2D) through beta-cell exhaustion. The higher the plasma glucose level with which a patient goes to bed as a result of postprandial hyperglycemia, the higher will be the fasting hyperglycemia in the morning. Similarly, the higher the fasting hyperglycemia in the morning, the higher the postprandial level during the day.

Related Links

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics EU Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Leaving the Biocon Biologics Corporate Website

You are now leaving the Biocon Biologics Corporate website for a Biocon Biologics U.S. Corporate microsite that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Leaving the Biocon Biologics site

You are now leaving the Biocon Biologics page for a Biocon Biologics affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon Biologics affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.